- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04283006
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
Study Overview
Status
Intervention / Treatment
Detailed Description
Relapsed/refractory hematological malignancies has a short survival time and a high mortality rate. A number of clinical trials in China and at abroad have shown that CAR T-cells targeting CD19 have a high remission rate and limited adverse effects in the treatment of relapsed/refractory leukemia, which has great clinical application prospect. The New England Journal (NEJM) reported in 2010 and 2013 that the Carl June's team at the University of Pennsylvania used CAR T-cells against CD19 to treat B-cell malignancies successfully. On August 30, 2017, the US FDA first approved Novartis CAR T-cells for the treatment of acute lymphocytic leukemia. Our center has completed the treatment of 33 cases of acute lymphoblastic leukemia with CAR-T cells targeting CD19, with a complete remission rate of 90% and 10 cases of lymphoma treated with CAR T-cells. At present, the international clinical trials of CD20 / CD22 dual-target CAR T-cells in the treatment of relapsed/refractory lymphoid hematological malignancies have achieved impressive results, but the number of patients needs to be further verified.
Based on the results of prior studies and the lack of effective treatment options for relapsed/refractory hematological malignancies, we have applied for a clinical trial of CD20 / CD22 dual-target CAR T-cells to treat relapsed/refractory hematological malignancy.
This is a single arm, open-label, single-center study. Patients with CD20 and CD22-positive relapsed/refractory hematological malignancies have an estimated survival of 2 years. The purpose is to evaluate the safety and effectiveness of CD20 / CD22 dual-target CAR T-cell therapy through this clinical trial study, and to provide clinical basis and experience for CAR T-cell technology in the treatment of clinical malignant hematological diseases.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Yongxian Hu, MD
- Phone Number: 86-15957162012
- Email: huyongxian2000@aliyun.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The First Hospital of Zhejiang Medical Colleage Zhejiang University
-
Contact:
- He Huang, MD.
- Phone Number: 86-13605714822
- Email: hehuangyu@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Criteria:
Inclusion Criteria:
Inclusion criteria applicable to ALL only:
- Male or female aged ≥ 3 and <70 years old;
- Histologically confirmed diagnosis of CD19+ B-ALL per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphoblastic Leukemia (2016.v1);
Relapsed or refractory CD19+ B-ALL (meeting one of the following conditions):
- CR not achieved after standardized chemotherapy;
- CR achieved following the first induction, but CR duration is ≤ 12 months;
- Ineffective after first or multiple remedial treatments;
- 2 or more recurrences;
- The number of primordial cells (lymphoblast and prolymphocyte) in bone marrow is >5% (morphology) and/or >1% (Flow cytometry);
- Philadelphia-chromosome-negative (Ph-) patients; or Philadelphia-chromosome- positive (Ph+) patients who cannot tolerate TKI treatments or do not respond to 2 TKI treatments;
Inclusion criteria applicable to NHL only:
- Male or female aged ≥ 18 and <70 years old;
- Histologically confirmed diagnosis per WHO Classification Criteria for Lymphocytic Tumors 2016, including DLBCL(NOS), follicular lymphoma, Chronic lymphoblastic leukemia/small lymphoblastic lymphoma transforms DLBCL, PMBCL and high grade B cell lymphoma;
Relapsed or refractory DLBCL (meeting one of the following conditions):
- No remission or recurrence after receiving second-line or above second-line chemotherapy;
- Primary drug resistance;
- Recurrence after autologous hematopoietic stem cell transplantation;
- According to Lugano 2014, there should be at least one evaluable tumor lesion.
Applicable standards for ALL and NHL:
- HLA antibody(-) or HLA antibody(+) and HLA donor specific antibody(DSA)(-);
- total bilirubin ≤ 51umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8umol/L;
- Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;
- No active infection in the lungs, blood oxygen saturation by sucking air is ≥ 92%;
- Estimated survival time ≥ 3 months;
- ECOG performance status 0 to 2;
- Patients or their legal guardians volunteer to participate in the study and sign the informed consent.
Exclusion Criteria:
- patients with extramedullary lesions, except those with CNSL (CNS-1) under effective control (for ALL patients only);
- Confirmed diagnosis of lymphoblastic crisis of chronic myeloid leukemia, Burkitt's leukemia/lymphoma per WHO Classification Criteria (for ALL patients only);
- Patients with hereditary syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome (for ALL patients only);
- Patients with intracranial extralateral lesions (cerebrospinal fluid tumor cells and/or intracranial lymphoma invasion shown by MRI) (for NHL patients only) ;
- Extensive involvement of gastrointestinal lymphoma (for NHL patients only);
- Radiotherapy, chemotherapy and monoclonal antibody within 1 week before screening;
- Have a history of allergy to any of the components in the cell products;
- Prior treatment with any CAR T cell product or other genetically-modified T cell therapies;
- According to the New York heart association (NYHA) cardiac function classification criteria, Subjects with grade III or IV cardiac insufficiency;
- Myocardial infarction, cardioangioplasty or stenting, unstable angina pectoris, or other severe cardiac diseases within 12 months of enrollment;
- Severe primary or secondary hypertension of grade 3 or above (WHO Hypertension Guidelines, 1999);
- Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
- History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases;
- Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis).
- Indwelling catheters in vivo (e.g. percutaneous nephrostomy, Foley catheter, bile duct catheter, or pleural/peritoneal/pericardial catheter). Ommaya storage, dedicated central venous access catheters such as Port-a-Cath or Hickman catheters are allowed;
History of other primary cancer, except for the following conditions:
- Cured non-melanoma after resection, such as basal cell carcinoma of the skin;
- Cervical cancer in situ, localized prostate cancer, ductal cancer in situ with disease-free survival ≥ 2 years after adequate treatment;
- Patients with autoimmune diseases requiring treatment, patients with immunodeficiency or requiring immunosuppressive therapy;
- Patients with graft-versus-host disease (GVHD);
- Prior immunizations with live vaccine 4 weeks prior to screening;
- History of alcoholism, drug abuse or mental illness;
- If HBsAg positive at screening, HBV DNA copy number detected by PCR in patients with active hepatitis B > 1000 (if HBV DNA copy number≤1000, routine antiviral therapy is required after enrollment), as well as CMV, hepatitis C, syphilis infection;
- Concurrent therapy with systemic steroids within 1 week prior to screening, except for the patients recently or currently receiving inhaled steroids;
- Patients who have participated in any other clinical studies within 2 weeks prior to screening;
- Pregnant and breast-feeding women and the subjects who are fertile and unable to take effective contraceptive measures (regardless of the gender);
- Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Administration of CD20/CD22 dual Targeted CAR T-cells
A dose levels of 3-5*10E6/kg are administrated for each subject.
|
Each subject receive CD20/CD22 dual Targeted CAR T-cells by intravenous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicity (DLT)
Time Frame: Baseline up to 28 days after CD20/CD22 targeted CAR T-cells infusion
|
Adverse events assessed according to NCI-CTCAE v5.0 criteria
|
Baseline up to 28 days after CD20/CD22 targeted CAR T-cells infusion
|
Incidence of treatment-emergent adverse events (TEAEs)
Time Frame: Up to 2 years after CD20/CD22 targeted CAR T-cells infusion
|
Incidence of treatment-emergent adverse events [Safety and Tolerability]
|
Up to 2 years after CD20/CD22 targeted CAR T-cells infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
B-cell acute lymphocytic leukemia (B-ALL), MRD negative overall response rate (MRD- ORR)
Time Frame: 3 months
|
Assessment of MRD negative overall response rate (MRD- ORR) at 3 months after CD20/CD22 targeted CAR T-cells infusion
|
3 months
|
B-ALL, Event-free survival (EFS)
Time Frame: Month 6, 12, 18 and 24
|
From the first infusion of CD20/CD22 targeted CAR T-cells to the occurrence of any event, including death, relapse or gene relapse, disease progression (any one occurs first), and the last visit
|
Month 6, 12, 18 and 24
|
B-ALL, Overall response rate (ORR)
Time Frame: Month 6, 12, 18 and 24
|
Assessment of ORR (ORR = CR + CRi ) at Month 6, 12, 18 and 24
|
Month 6, 12, 18 and 24
|
B-ALL, Overall survival (OS)
Time Frame: Month 6, 12, 18 and 24
|
From the first infusion of CD20/CD22 targeted CAR T-cells to death or the last visit
|
Month 6, 12, 18 and 24
|
B cell non-hodgkin's lymphoma (B-NHL), Overall response rate (ORR)
Time Frame: weeks 4, 12, months 6, 12, 18 and 24
|
Assessment of ORR (ORR = CR + PR ) per Lugano 2014 criteria
|
weeks 4, 12, months 6, 12, 18 and 24
|
B-NHL, disease control rate (DCR)
Time Frame: weeks 12, months 6, 12, 18 and 24
|
Assessment of DCR (DCR=CR+PR+SD) per Lugano 2014 criteria
|
weeks 12, months 6, 12, 18 and 24
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CD20/CD22-ZhejiangU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed and Refractory
-
Case Comprehensive Cancer CenterFlorida International University; Community Foundation of BrowardRecruitingRelapsed Cancer | Refractory CancerUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Technische Universität DresdenAbbVieActive, not recruitingRelapsed Adult AML | Refractory AMLGermany
-
Nantes University HospitalWithdrawnCD22+ Relapsed/Refractory B-ALLFrance
-
Stanford UniversityAmgen; Pediatric Oncology Experimental Therapeutics Investigators' ConsortiumCompletedRefractory Leukemia | Refractory Solid Tumors | Relapsed Solid Tumors | Relapsed LeukemiaUnited States, Canada
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingRelapsed/Refractory B-Cell MalignanciesChina, Australia
-
Minghui Pharmaceutical (Shanghai) LTDRecruitingRelapsed/Refractory B-cell MalignanciesChina
-
Gilead SciencesCompletedRelapsed/Refractory B-cell MalignanciesFrance, United Kingdom
-
OncoMed Pharmaceuticals, Inc.CompletedRelapsed or Refractory Lymphoid MalignanciesUnited States
-
Xinxiang medical universityRecruiting
Clinical Trials on CD20/CD22 dual Targeted CAR T-cells
-
Southwest Hospital, ChinaUnknown
-
Chinese PLA General HospitalUnknownB Cell Lymphoma | B Cell LeukemiaChina
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Southwest Hospital, ChinaUnknown
-
Hrain Biotechnology Co., Ltd.Ruijin HospitalNot yet recruitingAcute Lymphoblastic LeukemiaChina
-
Hrain Biotechnology Co., Ltd.Second Affiliated Hospital of Nanchang UniversityRecruitingCentral Nervous System LymphomaChina
-
Chongqing Precision Biotech Co., LtdRecruitingLymphoma, B-Cell | Leukemia, B-cellChina
-
Chongqing Precision Biotech Co., LtdRecruitingLymphoma, B-Cell | Leukemia, B-cellChina
-
Chongqing Precision Biotech Co., LtdRecruiting
-
Chongqing Precision Biotech Co., LtdRecruiting